Document Type: Research Articles
Department of Clinical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Department of Genetics, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Background: Breast cancer is the most common malignancy in women. Multidrug resistance (MDR) is still a great
obstacle of breast cancer chemotherapy. We have previously shown that multidrug resistance-associated protein 1 (MRP1)
is associated with response to neoadjuvant chemotherapy. The lung resistance-related protein (LRP) is identified as
a prognostic marker and response to treatment factor which has been studied mainly in hematological malignancy and
leukemia. In this study, we aimed to analyze LRP expression and possible correlation between the expression level of
this gene with MRP1 as a candidate marker for chemotherapy resistance. Materials and Methods: We collected 54
breast tumors and adjacent normal tissues from Iranian breast cancer patients and Real time RT-PCR was employed to
measure the gene expression level in our samples. Results: MRP1 and LRP expression level were significantly lower
in tumor tissues of the patients responding to chemotherapy compared to non-responding patients. No relation between
the expression level of either of these genes and clinicopathology markers was found. Conclusion: Our results suggest
that LRP gene expression is correlated to MRP1 in human breast cancer cells and may affect the clinical response to